Drug Trial Radar · NCT06939777
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
255
Actual
Start
Apr 28, 2025
Primary completion
Dec 8, 2025
Study completion Mar 17, 2026
Sponsor
- Lead sponsor
- Sinovac Life Sciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 59 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the full human anti-tetanus toxin monoclonal antibody SNA02-48 injection and compare the Tetanus-antibody levels and safety of SNA02-48 with human tetanus immunoglobulin (HTIG) in Chinese adult participants.
Conditions
- Tetanus
Interventions
SNA02-48Biological
intramuscular injection
PlaceboBiological
intramuscular injection
HTIGBiological
intramuscular injection
Tetanus ToxoidBiological
intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse reactionsTime frame: Up to 105 days
- The increase in serum tetanus antibody levels from baseline at 12 hours post-administrationTime frame: 12 hours after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Hospital of Anhui Medical Universiy
Hefei, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.